Understanding the Link Between Chronic Kidney Disease and Anemia

Anemia is a near-universal complication of advanced chronic kidney disease (CKD), affecting >90% of dialysis patients. It drives fatigue, cardiovascular morbidity, cognitive decline, and mortality. Understanding the multifactorial pathophysiology guides targeted therapy.

Pathophysiology: Four Pillars

MechanismPathophysiologyClinical Correlate
1. EPO DeficiencyPeritubular fibroblasts (kidney) produce erythropoietin (EPO) in response to hypoxia. CKD → fibroblast loss → ↓ EPO → ↓ erythropoiesis.Normocytic, normochromic anemia; reticulocytopenia.
2. Iron Restriction
  • Absolute deficiency: blood loss (HD, GI), poor intake.
  • Functional deficiency: hepcidin ↑ (inflammation) → ferroportin degradation → iron trapped in macrophages/enterocytes.
Low TSAT (<20%), low/normal ferritin (acute phase reactant).
3. Blood LossHD circuit, frequent phlebotomy, uremic platelet dysfunction → GI bleeding, epistaxis.Iron deficiency anemia superimposed.
4. Uremic Toxin SuppressionIS, PCS, ADMA inhibit erythroid progenitors; shorten RBC lifespan (↓ 60–80 days).EPO resistance; reduced RBC survival.

Additional Contributors

  • Folate/B12 deficiency (dialysis loss, poor intake).
  • Aluminum toxicity (historical).
  • Secondary hyperparathyroidism → bone marrow fibrosis.
  • Malnutrition-inflammation complex (MICS).

Diagnostic Workup

  • CBC, reticulocyte count, iron studies (ferritin, TSAT, hepcidin emerging).
  • Rule out other causes: B12/folate, hemolysis (LDH, haptoglobin, bilirubin), blood loss.
  • KDIGO: evaluate anemia when Hb <13 g/dL (men), <12 g/dL (women).

Treatment: KDIGO 2024 Framework

Iron Repletion (First)

  • Target: TSAT ≥30%, ferritin ≥100–500 ng/mL (ND-CKD); ≥200–500 (HD).
  • IV iron preferred in dialysis/ESA-treated (bypasses hepcidin); oral if ND-CKD, no inflammation.
  • Modern IV irons (ferric carboxymaltose, ferumoxytol, iron isomaltoside) allow high-dose, rapid infusion.

Erythropoiesis-Stimulating Agents (ESAs)

  • Indication: Hb <10 g/dL (symptomatic) or individualized; target 10–11 g/dL (<11.5).
  • Agents: epoetin alfa/beta, darbepoetin alfa, methoxy PEG-epoetin beta (CERA).
  • Dosing: weight-based, subcutaneous preferred (longer half-life); titrate to avoid rapid Hb rise (>1 g/dL/2 wk).
  • Risks: Stroke, thrombosis, hypertension, tumor progression (cancer), pure red cell aplasia (rare, antibody-mediated).

HIF-PH Inhibitors (New Class)

  • Roxadustat, vadadustat, daprodustat (oral).
  • Stabilize HIF → endogenous EPO ↑ + iron mobilization (hepcidin ↓) + erythroid maturation.
  • Advantages: oral, physiological EPO pattern, iron utilization.
  • Cautions: thrombosis risk (similar to ESA), not approved in US for dialysis (FDA CRL); approved in EU/Japan/China.

Monitoring

  • Hb q2–4 weeks during initiation/titration; monthly stable.
  • Iron studies q1–3 months.
  • BP, vascular access, seizure risk.

Anemia in CKD is treatable. Individualized, physiology-guided therapy improves quality of life and cardiovascular outcomes.

Kidney Disease - Related Articles